GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (XAMS:BAI) » Definitions » Short Percentage of Float

Benevolent AI (XAMS:BAI) Short Percentage of Float


View and export this data going back to 2022. Start your Free Trial

What is Benevolent AI Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Benevolent AI's Short Percentage of Float

For the Biotechnology subindustry, Benevolent AI's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benevolent AI's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benevolent AI's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Benevolent AI's Short Percentage of Float falls into.


Benevolent AI Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (XAMS:BAI) » Definitions » Short Percentage of Float
Comparable Companies
XAMS:VVY OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX SZSE:300122 BGNE ALNY OCSE:GMAB BMRN XKRX:068270 XBRU:UCB RPRX INCY
Traded in Other Exchanges
2XA:Germany
Address
4-8 Maple Street, London, GBR, W1T 5HD
Website
https://www.benevolent.com
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.

Benevolent AI Headlines